Pfizer Fields Novo’s $10B Curveball, With Bourla Promising To Fight for Metsera

Novo Nordisk has escalated its bidding war for obesity biotech Metsera, offering $10 billion to outbid Pfizer's revised $8.1 billion proposal, intensifying a legal dispute where Pfizer alleges antitrust violations and 'tortious interference.' Concurrently, Pfizer reported strong third-quarter earnings, with revenue of $16.65 billion and EPS of $0.87, significantly exceeding consensus estimates due to cost savings and a low tax rate, leading to an increased full-year EPS guidance, despite mixed product performance including strong Eliquis sales but declining Paxlovid revenue.

Analysis

Pfizer is embroiled in an escalating bidding war for obesity biotech Metsera, with Novo Nordisk's $10 billion offer now surpassing Pfizer's $8.1 billion bid, which Metsera has deemed superior. Pfizer has initiated litigation, alleging "tortious interference" and potential antitrust violations by Novo Nordisk, while CEO Bourla defends Pfizer's pursuit, citing extensive due diligence and the early termination of the Hart-Scott-Rodino waiting period. This contentious M&A battle introduces significant uncertainty and potential legal costs.

Concurrently, Pfizer reported robust third-quarter results, with revenue of $16.65 billion and EPS of $0.87, significantly exceeding consensus by 38% due to lower costs and a favorable tax rate. Key products like Eliquis grew 22% to $2 billion, and Comirnaty beat expectations by 8%, leading to an increased full-year EPS guidance from $3 to $3.08. This demonstrates strong operational execution and effective cost management.

However, product performance was mixed, as Paxlovid revenue declined 55% operationally, missing consensus by 9%, and newer assets like Vyndaqel and Padcev underperformed expectations. While the oncology portfolio drove growth, analysts noted the revenue beat was largely from less-focused products. Investors should closely monitor the future sales trajectory of Pfizer's COVID franchise given recent regulatory changes.

Key Decisions for Investors

• Monitor the Metsera bidding war and associated litigation for Pfizer, as the outcome will significantly impact strategic direction and capital allocation, potentially introducing substantial legal and integration risks.
• Assess Pfizer's underlying operational strength, evidenced by its Q3 earnings beat and raised EPS guidance, but remain vigilant regarding the mixed performance of newer assets and the declining COVID franchise.
• Evaluate the long-term implications of Pfizer's aggressive M&A strategy in obesity, considering the high valuations and potential for increased R&D and acquisition-related expenses against the company's cost-cutting initiatives.